Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P06126 (
CD1a
)
2,221
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Langerhans cell histiocytosis (LCH) is a MAPK pathway-driven disease characterized by the accumulation of
CD1a
+
langerin
+
cells of unknown origin. We have previously reported that the Notch signaling pathway is active in LCH lesions and that the Notch ligand
Jagged2
(
JAG2
) induces
CD1a
and langerin expression in monocytes in vitro. Here we show that Notch signaling induces monocytes to acquire an LCH gene signature and that Notch inhibition suppresses the LCH phenotype. In contrast, while also CD1c
+
dendritic cells or IL-4-stimulated CD14
+
monocytes acquire
CD1a
and langerin positivity in culture, their gene expression profiles and surface phenotypes are more different from primary LCH cells. We propose a model where CD14
+
monocytes serve as LCH cell precursor and
JAG2
-mediated activation of the Notch signaling pathway initiates a differentiation of monocytes toward LCH cells in selected niches and thereby contributes to LCH pathogenesis.
...
PMID:JAG2 signaling induces differentiation of CD14
+
monocytes into Langerhans cell histiocytosis-like cells. 3029 38
